USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Peng, Jing ^a,b,c   Hu, Qian ^a,b,c   Liu, Weiping ^d   He, Xiaoli ^e   Cui, Ling ^f   Chen, Xinlian ^a,b,c   Yang, Mei ^a,b,c   Liu, Hongqian ^a,b,c   Wei, Wei ^a,b,c   Liu, Shanling ^a,b,c   Wang, He ^a,b,c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d SICHUAN UNIVERSITY   (China)

^e HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f SICHUAN CANCER HOSPITAL   (China)

Author keywords

Esophageal squamous cell cancer; Survival; Tumor progression; Ubiquitin specific protease 9x

Indexed keywords

TUMOR MARKER; UBIQUITIN THIOLESTERASE; USP9X PROTEIN, HUMAN;

ARTICLE; CELL TRANSFORMATION; COMPARATIVE STUDY; DISEASE COURSE; EPITHELIUM; ESOPHAGUS TUMOR; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIUM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN THIOLESTERASE; UP-REGULATION;

EID: 84886037235     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-177     Document Type: Article

References (32)

1. Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T, Kuwano H. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009, 16:506-514. 10.1245/s10434-008-0252-0, 19050962.
2. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G, Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005, 11:6190-6197. 10.1158/1078-0432.CCR-04-2553, 16144920.
3. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003, 97:1616-1623. 10.1002/cncr.11228, 12655517.
4. Shirakawa Y, Naomoto Y, Kimura M, Kawashima R, Yamatsuji T, Tamaki T, Hamada M, Haisa M, Tanaka N. Topological analysis of p21WAF1/CIP1 expression in esophageal squamous dysplasia. Clin Cancer Res 2000, 6:541-550.
5. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010, 70(22):9265-9276. 10.1158/0008-5472.CAN-10-1530, 21045142.
6. Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, Dong L, Tang E, Yang H. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat 2007, 104(1):21-30. 10.1007/s10549-006-9393-7, 17004105.
7. Xue LY, Hu N, Song YM, Zou SM, Shou JZ, Qian LX, Ren LQ, Lin DM, Tong T, He ZG, Zhan QM, Taylor PR, Lu N. Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. BMC Cancer 2006, 6:296. 10.1186/1471-2407-6-296, 1766359, 17187659.
8. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009, 15:1915-1922. 10.1158/1078-0432.CCR-08-2545, 19276261.
9. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006, 22:159-180. 10.1146/annurev.cellbio.22.010605.093503, 16753028.
10. Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 2009, 8:1688-1697. 10.4161/cc.8.11.8739, 19448430.
11. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397. 10.1146/annurev.biochem.78.082307.091526, 2734102, 19489724.
12. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009, 10:550-563. 10.1038/nrm2731, 19626045.
13. Quesada V, Díaz-Perales A, Gutiérrez-Fernández A, Garabaya C, Cal S, López-Otín C. Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases. Biochem Biophys Res Commun 2004, 314(1):54-62. 10.1016/j.bbrc.2003.12.050, 14715245.
14. Jones MH, Furlong RA, Burkin H, Chalmers IJ, Brown GM, Khwaja O, Affara NA. The Drosophila developmental gene fat facets has a human homologue in Xp11.4 which escapes X-inactivation and has related sequences on Yq11.2. Hum Mol Genet 1996, 5(11):1695-1701. 10.1093/hmg/5.11.1695, 8922996.
15. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463(7277):103-107. 10.1038/nature08646, 20023629.
16. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 2011, 117(11):3151-3162. 10.1182/blood-2010-03-276477, 21248063.
17. Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MK, Smythe WR, Cao X. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer 2012, 12:541. 10.1186/1471-2407-12-541, 3543233, 23171055.
18. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors 2009, Hoboken: Wiley, 7.
19. Lijun H, Qiang L, Yong H, Zhe L, Zhipei Z, Xiaofei L. ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol 2012, 7:180. 10.1186/1746-1596-7-180, 3542252, 23244569.
20. Ortiz CM, Tetsuo I, Yosuke H, Satoshi N, Akira I, Shigeru T, Fumiaki S, Miguel M, Jose G, Ana P, Yutaka S. Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines. Diagn Pathol 2010, 5:41. 10.1186/1746-1596-5-41, 2907320, 20565981.
21. Li SH, Tian H, Yue WM, Li L, Gao C, Li WJ, Hu WS, Hao B. Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World J Surg 2012, 36(3):623-631. 10.1007/s00268-011-1421-z, 22270988.
22. Lin FR, Huang SY, Hung KH, Su ST, Chung CH, Matsuzawa A, Hsiao M, Ichijo H, Lin KI. ASK1 promotes apoptosis of normal and malignant plasma cells. Blood 2012, 120(5):1039-1047. 10.1182/blood-2011-12-399808, 22723553.
23. Kitamura K, Kuwano H, Yasuda M, Sonoda K, Sumiyoshi K, Tsutsui S, Kitamura M, Sugimachi K. What is the earliest malignant lesion in the esophagus?. Cancer 1996, 77:1614-1619.
24. Shi ST, Yang GY, Wang LD, Xue Z, Feng B, Ding W, Xing EP, Yang CS. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999, 20:591-597. 10.1093/carcin/20.4.591, 10223186.
25. Sugiura K, Ozawa S, Kitagawa Y, Ueda M, Kitajima M. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 2007, 17:557-564.
26. Christein JD, Hollinger EF, Millikan KW. Prognostic factors associated with resectable carcinoma of the esophagus. Am Surg 2002, 68:258-262. discussion 262-263.
27. Wong R, Malthaner R. Esophageal cancer: a systematic review. Curr Probl Cancer 2000, 24:297-373.
28. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354(23):2419-2430. 10.1056/NEJMoa055351, 16760442.
29. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9(4):313-325. 10.1016/j.ccr.2006.03.019, 16616336.
30. Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL, Wofford JA, Dimascio LN, Ilkayeva O, Kelekar A, Reya T, Rathmell JC. Glycogen synthase kinase 3α and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 2007, 27(12):4328-4339. 10.1128/MCB.00153-07, 1900055, 17371841.
31. Van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10(5):389-399. 10.1016/j.ccr.2006.08.027, 2953559, 17097561.
32. Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, Ten Hoeve JJ, De Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM, Wessels LF. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012, 486(7402):266-270. 3376394, 22699621.